in Health care
CDSCO Panel Grants Abbott’s Protocol Amendment Proposal For Ursodeoxycholic Acid
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has accepted Abbott’s phase III clinical trial protocol amendment proposal for Ursodeoxycholic Acid Tablets IP 150 mg, 300 mg, 450 mg, and 600 mg with respect to inclusion and exclusion criteria. Ursodeoxycholic acid, or ursodiol, is a naturally occurring […] More
